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Abstract— EGF receptor-binding peptides could be found by a peptide screening method using fifteen fluorescent amino acids as 
fluorescent tags. Of two hundred twenty-five peptides, we found an 8-mer peptide containing a dipeptide unit, Y-F, which was the 
strongest binding peptide to the EGF receptor. 
Peptide screening methods such as the phage display 
method1 and one-bead-one-compound (OBOC) 
method2,3 have been widely used for identifying the 
peptides binding to target proteins. However, these 
methods essentially need very large carriers such as 
phages and beads to fix the peptides, and use of the 
carriers often has the drawback of peptides binding to 
target proteins not being able to be accurately found due 
to nonspecific interaction between target proteins and 
the carriers.4 
To resolve this drawback, we have recently 
developed a new peptide screening method using 
multiple fluorescent amino acids as fluorescent tags 
instead of using such carriers.5 By this method, target 
protein-binding peptides can be quantified from 
fluorescence intensity of each peptide labeled with a 
fluorescent amino acid, and accurate peptide screening 
is expected because target protein-binding peptides can 
be found by this method without the use of large 
carriers. 
In this study, we carried out quantitative screening of 
peptides binding to the EGF receptor6,7 (epidermal 
growth factor receptor = EGFR) by using this method. 
EGFR is a cell-surface receptor. Mutations affecting 
EGFR expression or activity can result in cancer. 
Therefore, an EGFR-binding peptide is an attractive 
medical tool, and some research groups have searched 
for such a peptide by using phage display methods.8–11 
First, we prepared fifteen peptides containing a 
fluorescent amino acids12 (fluorescent peptides) as one 
set of fluorescent peptide by conventional Fmoc-based 
solid-phase peptide synthesis.13-16 The chemical 
structures of the peptides and the fluorescent amino 
acids17 are shown in Fig. 1. The sequences are Ac-EE-
Fl-EE-Sp6-XXX-Y1-Y2-XXX-NH2.18 Fl indicates a 
fluorescent amino acid. Fifteen fluorescent amino acids 
are used in this study. To improve water solubility, four 
D-glutamic acids are connected with the fluorescent 
amino acid. X indicates an equimolar mixture of fifteen 
D-configurated natural amino acids other than Cys, Glu, 
Gly, Leu and Gln.19 Y1 and Y2 are any one of the fifteen 
D-configurated natural amino acids.20 The 8-mer peptide 
consisting of X, Y1 and Y2 is a library moiety. Sp6 (a 
long spacer consisting of ethylene glycol units) connects 
the fluorescent amino acid with the library moiety. Ac 
indicates an acetyl group. The C-terminals of the 
peptides are primary amides. We prepared in total 15 
sets of fifteen fluorescent peptides (two hundred twenty-
five fluorescent peptides consisting of different Y1-Y2; 
Figure S4, Supporting Information). We also prepared 
fifteen fluorescent peptides consisting of a random 
library moiety (Ac-EE-Fl-EE-Sp6-XXX-X-X-XXX-
NH2), and two-dimensional fluorescence (2D-FL) 
spectra of the fluorescent peptides were measured as 
component spectra as described below (Figure S5, 
Supporting Information).  
Next, to examine whether these fluorescent peptides 
can be discriminated and quantified by least-squares 
analysis from a 2D-FL spectrum of the mixture of 
 
fifteen fluorescent peptides on the basis of component 
spectra, we measured the 2D-FL spectrum of the 
mixture of fifteen fluorescent peptides prepared with 
various predetermined concentrations. And we 
estimated each concentration of the fluorescent peptides 
by aforementioned method (Fig. 2).21 The calculated 
concentrations of fluorescent peptides were in fair 
agreement with the predetermined concentrations. It 
was shown that fifteen types of fluorescent peptides 
could be discriminated and quantified at the nM order 
(pmol order).  
Finally, peptides binding to the EGFR were selected 
and quantified by the method using these fluorescent 
peptides. In this study, the water-soluble ErbB1 
(sErbB1; the extracellular domain of human EGFR) was 
used as an EGFR.22 Fifteen fluorescent peptides were 
incubated with the EGFR in 70 mM HEPES-NaOH 
buffer (pH 7.4, 150 mM NaCl) at 4 ˚C for 2 h. Each 
final concentration of the peptides was 190 μM (4.5 
nmol) and the concentration of EGFR was 8.6 μM (0.36 
nmol). The fluorescent peptides binding to EGFR were 
recovered by gel filtration chromatography (SuperdexTM 
75 prep grade was purchased from GE Healthcare 
(London, UK).). Then the amounts of fluorescent 
peptides binding to the EGFR were determined with 
2D-FL spectroscopy in 70 mM HEPES-NaOH buffer 
(pH 7.4, 150 mM NaCl)/methanol (1/1 (v/v)). The 
binding of each fluorescent peptide to EGFR was 
quantified by least-squares analysis from the 2D-FL 
spectrum. We repeated the aforementioned protocols for 
15 sets of fifteen fluorescent peptides. These results are 
shown in Fig. 3.  
These fluorescent peptides were successfully 
estimated by this method, and it was shown that the 
amount of the peptide binding to the EGFR depends on 
a dipeptide unit, Y1-Y2, in the 8-mer peptide library. 
Many fluorescent peptides did not bind to the EGFR, 
but binding of some of the peptide to the EGFR could 
be detected.23 Of the fluorescent peptides, Ac-EE-Fam-
EE-Sp6-XXX-Y-F-XXX-NH2 was found to show the 
strongest binding to the EGFR. The binding amount of 
the peptide was 41 pmol. The reverse sequence, F-Y, 
showed weak binding to the EGFR (9 pmol). It was 
clarified that the sequence is important for binding to 
the EGFR. Dipeptide units containing amino acids 
carrying an aromatic ring (F, Y and W) and a 
hydrophobic group (I and V) seemed to bind to the 
EGFR strongly. This result indicates that the peptides 
binding to EGFR were successfully discriminated and 
quantified by this method.  
In summary, we synthesized two hundred twenty-
five peptides modified with a fluorescent amino acid as 
fluorescent tags for screening EGFR-binding peptides. 
Binding amounts of peptides to the EGFR were 
successfully quantified by this method. The 8-mer 
peptide containing a dipeptide unit, Y-F, was the 
strongest binding peptide to the EGFR. Determination 
of an 8-mer peptide sequence that binds to the EGFR by 
this method is currently underway. 
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Figure 1. Chemical structure of the peptide modified with a fluorescent 
amino acid and chemical structures of fifteen fluorescent amino acids. 
Values in a parenthesis indicate maximum excitation/emission 
wavelengths obtained from the 2D-FL spectrum of each fluorescent 
amino acid in 70 mM HEPES buffer (pH 7.4)/methanol (1/1 (v/v)) at 
room temperature. 
 
 
Figure 2. .Concentrations of fifteen fluorescent peptides consisting of a 
random library moiety estimated from the 2D-FL spectrum of the mixture 
of peptides by least-squares analysis. Each concentration of Hmc, Fam, 
Dec, Mac and Moc is 15 nM. Each concentration of Tmr, Cm3, Hoc, 
Acd and Coc is 10 nM. Each concentration of @52, A43, S39, Aca and 
Cmr is 5 nM. The spectrum of the mixture and component spectra were 
 
measured in 70 mM HEPES-NaOH buffer (pH 7.4, 150 mM 
NaCl)/methanol (1/1 (v/v)). 
 
 
Figure 3. Map of binding amounts of the peptides to the EGFR estimated 
from 2D-FL spectra by least-squares analysis. Each value in cells 
indicates the amount of peptide binding to EGFR (pmol). 
